RxDoctor Payments DataLook up a doctor →

Gerardo Bueso, MD

Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1578658001

Payments from drug & device makers

$1,168,028in general payments, 2019–2025

Across 1,368 payments — averaging $853.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$475K
  • AstraZeneca$419K
  • Kowa Research Institute, Inc.$133K
  • Sanofi US Services Inc.$73K
  • Boehringer Ingelheim$24K
  • Astrazeneca UK Limited$9K
  • plus $35K from 54 others
$5,208in research payments, 2019–2025

Across 2 payments — averaging $2603.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$5K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly8$474,823
AstraZeneca56$419,057
Kowa Research Institute, Inc.39$133,314
Sanofi US Services Inc.19$73,475
Boehringer Ingelheim67$23,853
Astrazeneca UK Limited2$8,628
Pfizer14$7,192
Amryt Pharma Holdings Ltd9$2,976
Chiasma, Inc.2$2,517
Novo Nordisk157$2,250
Abbott65$1,915
Akebia Therapeutics Inc4$1,852
Amgen(2 entities)99$1,583
Mannkind Corporation105$1,471
Lilly USA, LLC65$983
Bayer51$899
Amarin Pharma, Inc.56$859
Corcept Therapeutics38$775
Zealand Pharma US, Inc.49$760
Boehringer Ingelheim International GmbH11$760
AbbVie(2 entities)51$687
Sanofi-aventis U.S. LLC40$641
Medtronic(2 entities)39$622
Dexcom, Inc.34$587
Recordati_rare_diseases_inc.25$537
Merck25$417
Xeris Pharmaceuticals, Inc.24$412
Novartis17$367
Esperion Therapeutics, Inc.21$356
Ascendis Pharma Endocrinology Inc13$344
Regeneron Healthcare Solutions, Inc.10$232
Takeda Pharmaceuticals U.S.A., Inc.5$222
Cequr Corporation4$213
Johnson & Johnson7$195
Valeritas, Inc.15$168
Amneal Pharmaceuticals LLC10$156
BETA Bionics, Inc.10$150
Vivus LLC10$146
Exact Sciences6$123
BD6$116
Ipsen Biopharmaceuticals, Inc5$110
Antares Pharma, Inc.6$110
Astellas Pharma US Inc7$106
Neurocrine Biosciences, Inc.4$103
Radius Health, Inc.6$96
IBSA Pharma Inc.6$94
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$83
Intuity Medical Inc4$82
Kyowa Kirin, Inc.3$65
EUSA Pharma (US) LLC3$60
Shire North American Group Inc3$57
Averitas Pharma Inc.3$52
OPKO Pharmaceuticals, LLC3$48
Alvogen Inc2$46
Insulet Corporation3$41
Tandem Diabetes Care, Inc.2$33
Lifescan, Inc.2$32
Arbor Pharmaceuticals, Inc.2$31
Eisai Inc.2$26
Sequel Med Tech, LLC1$25

How this compares

$1,168,028 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$460,197
Medicare patients
531
Services billed
9,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →